4.8 Article Retracted Publication

被撤回的出版物: CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms (Retracted article. See vol. 132, 2022)

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 128, 期 6, 页码 2613-2625

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI98769

关键词

-

资金

  1. National Health and Medical Research Council of Australia (NHMRC) [1132519, 1098960]
  2. Dr. Mildred Scheel Stiftung fuer Krebsforschung
  3. Naito Foundation
  4. Senior Principal Research Fellowship [1078671]
  5. NH&MRC Early Career Fellowship [1124690]
  6. EMBO Long Term Fellowship ALTF [945-2015]
  7. National Health and Medical Research Council of Australia [1124690] Funding Source: NHMRC

向作者/读者索取更多资源

Critical immune-supressive pathways beyond programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) require greater attention. Nectins and nectin-like molecules might be promising targets for immunotherapy, since they play critical roles in cell proliferation and migration and exert immunomodulatory functions in pathophysiological conditions. Here, we show CD155 expression in both malignant cells and tumor-infiltrating myeloid cells in humans and mice. Cd155(-/-) mice displayed reduced tumor growth and metastasis via DNAM-1 upregulation and enhanced effector function of CD8(+) T and NK cells, respectively. CD155-deleted tumor cells also displayed slower tumor growth and reduced metastases, demonstrating the importance of a tumor-intrinsic role of CD155. CD155 absence on host and tumor cells exerted an even greater inhibition of tumor growth and metastasis. Blockade of PD-1 or both PD-1 and CTLA4 was more effective in settings in which CD155 was limiting, suggesting the clinical potential of cotargeting PD-L1 and CD155 function.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据